Regenxbio (RGNX) Q2 2024 earnings summary

Executive summary

• Significant progress in advancing gene therapy programs, including RGX-202 for Duchenne, RGX-314 for retinal diseases, and RGX-121 for Hunter syndrome, with positive clinical data and strong safety profiles reported.

• Accelerated regulatory timelines for RGX-314 in diabetic retinopathy, with pivotal trial initiation expected in H1 2025 and a potential $200 million milestone payment from AbbVie.

• RGX-121 pivotal trial met its primary endpoint, supporting a rolling BLA submission in Q3 2024 and potential priority review voucher in 2025.

• The company licenses its NAV Technology Platform, generating revenue from Zolgensma royalties and milestone payments, and completed a $131.1 million public offering to strengthen its cash position.

• Remains on track for first BLA filing in 2024 and pivotal trial initiations for Duchenne (H2 2024) and diabetic retinopathy (H1 2025).

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $327.3 million as of June 30, 2024, up from $314.1 million at year-end 2023, mainly due to $131.1 million in net proceeds from a public offering.

• Revenues for Q2 2024 were $22.3 million, up from $20.0 million in Q2 2023, mainly due to higher Zolgensma royalties.

• Net loss for Q2 2024 was $53.0 million ($1.05 per share), improved from $72.1 million ($1.66 per share) in Q2 2023.

• R&D expenses for Q2 2024 were $48.9 million, down from $59.9 million in Q2 2023, reflecting lower manufacturing and personnel costs.

• G&A expenses fell to $18.9 million from $23.7 million year-over-year.

Outlook and guidance

• Cash runway expected to fund operations into 2026, excluding potential milestone payments and priority review voucher monetization.

• Pivotal trial for RGX-202 in Duchenne planned for Q4 2024; pivotal trial for RGX-314 in diabetic retinopathy expected H1 2025.

• Rolling BLA submission for RGX-121 on track for Q3 2024, with potential approval and priority review voucher in 2025.

• Enrollment in pivotal ABBV-RGX-314 trials for wet AMD is on track, with regulatory submissions planned for H1 2026.

• Management expects continued operating losses and significant R&D spending as product candidates advance.